Pancreatic cancer(PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic ...Pancreatic cancer(PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic disease at time of diagnosis and the 5-year survival rate in these conditions is extremely low. For more than a decade gemcitabine has been the cornerstone of metastatic PDAC treatment, although survival benefit was very poor. PDAC cells are surrounded by an intense desmoplastic reaction that may create a barrier to the drugs penetration within the tumor. Recently PDAC stroma has been addressed as a potential therapeutic target. Nano albumin bound(Nab)-paclitaxel is an innovative molecule depleting tumor stroma, through interaction between albumin and secreted protein acidic and rich in cysteine. Addition of nab-paclitaxel to gemcitabine has showed activity and efficacy in metastatic PDAC first-line treatment improving survival and overall response rate vs gemcitabine alone in the MPACT phase Ⅲ study. This combination represents one of the standards of care in advanced PDAC therapy and is suitable to a broader spectrum of patients compared to other schedules. Nab-paclitaxel is under investigation as a backbone of chemotherapy in novel combinations with target agents or immunotherapy in locally advanced or metastatic PDAC. In this article, we provide an updated and critical overview about the role of nab-paclitaxel in PDAC treatment based on the latest advances in preclinical and clinical research. Furthermore, we focus on the use of nab-paclitaxel within the context of metastatic PDAC treatment landscape and we discuss about future implications in the light of current clinical ongoing trials.展开更多
目的:了解白蛋白紫杉醇(Nanoparticle Albumin Bound Paclitaxel,NAB-PTX)在医保患者中的临床使用以及报销情况,为NAB-PTX纳入医保支付后的报销管理提供参考。方法:结合《国家基本医疗保险、工伤保险和生育保险药品目录》(简称:《药品...目的:了解白蛋白紫杉醇(Nanoparticle Albumin Bound Paclitaxel,NAB-PTX)在医保患者中的临床使用以及报销情况,为NAB-PTX纳入医保支付后的报销管理提供参考。方法:结合《国家基本医疗保险、工伤保险和生育保险药品目录》(简称:《药品目录》),分析研究单位2021年9月至2022年2月NAB-PTX医保患者的临床使用及医保报销数据。对患者特征、疾病分布、药品用量、医保报销情况等进行描述性统计分析。采用Mann-Whiney U检验比较乳腺恶性肿瘤患者中NAB-PTX是否纳入报销对患者费用负担的影响。结果:医保患者使用NAB-PTX人次排名前三的疾病为乳腺恶性肿瘤、肺恶性肿瘤、食管恶性肿瘤。215人次符合医保支付条件,占使用总人次的7.19%。乳腺恶性肿瘤患者使用NAB-PTX排名前三的情况为乳腺癌术后辅助化疗、乳腺癌术前新辅助治疗、联合化疗失败的转移性乳腺癌。NAB-PTX纳入报销的患者自付费用与NAB-PTX未纳入报销的患者差异较大。结论:NAB-PTX在恶性肿瘤的治疗中应用广泛,2021年《药品目录》报销的覆盖范围有限,2022年《药品目录》取消NAB-PTX支付适应症限定后需要结合药品集中带量采购政策做好药物经济学评价以及基金支出预算分析。展开更多
文摘Pancreatic cancer(PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic disease at time of diagnosis and the 5-year survival rate in these conditions is extremely low. For more than a decade gemcitabine has been the cornerstone of metastatic PDAC treatment, although survival benefit was very poor. PDAC cells are surrounded by an intense desmoplastic reaction that may create a barrier to the drugs penetration within the tumor. Recently PDAC stroma has been addressed as a potential therapeutic target. Nano albumin bound(Nab)-paclitaxel is an innovative molecule depleting tumor stroma, through interaction between albumin and secreted protein acidic and rich in cysteine. Addition of nab-paclitaxel to gemcitabine has showed activity and efficacy in metastatic PDAC first-line treatment improving survival and overall response rate vs gemcitabine alone in the MPACT phase Ⅲ study. This combination represents one of the standards of care in advanced PDAC therapy and is suitable to a broader spectrum of patients compared to other schedules. Nab-paclitaxel is under investigation as a backbone of chemotherapy in novel combinations with target agents or immunotherapy in locally advanced or metastatic PDAC. In this article, we provide an updated and critical overview about the role of nab-paclitaxel in PDAC treatment based on the latest advances in preclinical and clinical research. Furthermore, we focus on the use of nab-paclitaxel within the context of metastatic PDAC treatment landscape and we discuss about future implications in the light of current clinical ongoing trials.
文摘目的:了解白蛋白紫杉醇(Nanoparticle Albumin Bound Paclitaxel,NAB-PTX)在医保患者中的临床使用以及报销情况,为NAB-PTX纳入医保支付后的报销管理提供参考。方法:结合《国家基本医疗保险、工伤保险和生育保险药品目录》(简称:《药品目录》),分析研究单位2021年9月至2022年2月NAB-PTX医保患者的临床使用及医保报销数据。对患者特征、疾病分布、药品用量、医保报销情况等进行描述性统计分析。采用Mann-Whiney U检验比较乳腺恶性肿瘤患者中NAB-PTX是否纳入报销对患者费用负担的影响。结果:医保患者使用NAB-PTX人次排名前三的疾病为乳腺恶性肿瘤、肺恶性肿瘤、食管恶性肿瘤。215人次符合医保支付条件,占使用总人次的7.19%。乳腺恶性肿瘤患者使用NAB-PTX排名前三的情况为乳腺癌术后辅助化疗、乳腺癌术前新辅助治疗、联合化疗失败的转移性乳腺癌。NAB-PTX纳入报销的患者自付费用与NAB-PTX未纳入报销的患者差异较大。结论:NAB-PTX在恶性肿瘤的治疗中应用广泛,2021年《药品目录》报销的覆盖范围有限,2022年《药品目录》取消NAB-PTX支付适应症限定后需要结合药品集中带量采购政策做好药物经济学评价以及基金支出预算分析。